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**What was known?**

Management of psoriasis is challenging in some conditions and combination therapy could be a solutionThere is lack of enough data on psoriasis combination therapy in IranMethotrexate is one of the commonly used drugs as part of psoriasis combination therapy.

Psoriasis is a chronic inflammatory disorder which has no definite cure despite various treatment modalities.\[[@ref1]\] Different factors are involved in the pathogenesis of this disease including biochemical, immunological, and vascular abnormalities and disturbance in epidermal proliferation and differentiation.\[[@ref2]\] Psoriasis is a common disorder with a prevalence ranging from 0.1% to 11.8%. Men and women are equally affected.\[[@ref3]\] Characteristic lesions of psoriasis are prominent raised plaques with a sharp border and scaly surface.\[[@ref4]\]

Psoriasis have different clinical subtypes which determine its clinical course and response to treatment.\[[@ref5]\] The type of the disease determines its clinical course and response to treatment.\[[@ref5]\] All the clinical variants of psoriasis can adversely affect the patient\'s quality of life, mainly through the unsightly appearance of the lesions that may lead to loss of self confidence, shame and sexual problems and consequently social isolation.\[[@ref6]\] Periods of self-healing occur in about half of the patients which can be from 1 year to several decades.\[[@ref7]\] Many treatment modalities have been introduced and extensively used for this disease. Because of the chronic nature of the disease, it is important for the treatments to be safe for long-term use.\[[@ref8]\] The use of many medications is limited due to the accumulative drug toxicity and in some instances, diminution of the drug\'s efficacy. Methotrexate (MTX) as one of the common drugs used in combination with other common systemic non-biologic anti-psoriatic regiments like cyclosporine, acetretin and PUVA, could be a potential drug affecting by interactions which related to the pharmacokinetic and pharmacodynamic issues.

MTX is one of the most efficacious medicines for psoriasis and is being used extensively for this purpose. It is regarded as the gold-standard treatment for severe psoriasis, especially in erythrodermic and diffuse pustular variants.\[[@ref9]\] This drug causes regression in the majority of the patients who continues with maintenance therapy.\[[@ref9]\] MTX is also effective in psoriatic arthritis.\[[@ref10]\] However, it is an anti-metabolite agent and has potentially life-threatening side effects. Some patients with psoriasis require combination therapy that could include MTX as a part of regimen for disease control.

In Iran, we have no comprehensive descriptive data about treatment responsibility and side effects of such combinations; therefore, in this study, we tried to collect the data of psoriatic patients who received MTX in combination with other systemic non-biologic therapies.

Materials and Methods {#sec1-2}
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In this study we evaluated patients with psoriasis who were referred to Razi Hospital, Tehran, Iran, from October 2008 to March 2012.

All patients with moderate to severe psoriasis who received MTX in combination with other systemic non-biologic anti-psoriatic treatment modalities for controlling their cutaneous disease were included in the study. It should be noted that these patients were candidates for combination therapy due to the lack of good response to initial routine treatments.

Demographic data including age and sex as well as type of psoriasis, type of treatment, duration and dosage of the systemic agents or phototherapy and side effects were obtained from the patient profiles.

The Psoriasis Area and Severity Index (PASI) was used to evaluate the treatment efficacy. A decrease of 75% or higher in the PASI score was regarded as good while response to therapy was considered intermediate and poor with 25% to 75% and less than 25% decrease in the PASI score, respectively.
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Forty-six psoriatic patients (32 males, 69.6%) were included in the study. The mean age of the participants was 36.6 ± 39.2 years old (ranging from 22 to 77 years). Six patients (13%), 21 patients (46%), and 11 patients (24%) received MTX in combination with narrow-band ultraviolet B phototherapy, acitretin, and cyclosporine, respectively. MTX was added to the therapeutic regimens of 8 patients (17%) under other treatments such as phototherapy, cyclosporine, or acitretin.

The dosage of MTX was between 5 and 15 mg per week in all the patients. The mean duration of MTX and cyclosporine combination therapy was 9.5 ± 2.5 months, and the mean duration of combination therapy with MTX and acitretin or phototherapy was about 15.3 ± 4.8 and 6.4 ± 2.1 months, respectively.

[Table 1](#T1){ref-type="table"} demonstrates the response rate in psoriatic patients receiving combination therapy with MTX. Overall, the response was good in 21 (46%), moderate in 12 (26%), and poor in 13 (28%) patients.

###### 

Response rate in patients receiving combination therapy with MTX

![](IJD-61-118c-g001)

The highest response was observed in patients receiving a combination of MTX and phototherapy (67%) or acitretin (62%). Overall, 32 out of 46 patients experienced side effects; however, none of them were severe and required discontinuation of treatment or hospitalization.
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In the present analytic descriptive retrospective study, we assessed the treatment responsibility and side effects of combination therapy with MTX plus other non-topical, non-biologic anti-psoriatic treatment modalities based on the observed treatment results. Non-topical, non-biologic treatments for psoriasis include MTX, phototherapy, cyclosporine, and acitretin. In this study, MTX plus acitretin was the most commonly used combination therapy for patients with moderate to severe psoriasis who were resistant to mono-therapy. Overall, about half of the patients showed good response when treated with MTX plus any of the other drugs. The highest response rate was observed in patients treated with MTX plus phototherapy (67%) and the second best response was observed with acitretin (62%).

Many studies have been conducted regarding combination therapy in psoriasis. In the majority of these studies, MTX has been shown to be more efficacious when used in combination with other treatment modalities than when used alone. Philip and colleagues (2012) reported acitretin and cyclosporine as the second best combinations with MTX after biologics as the best non-biologic combinations. Side effects were observed in 18 patients, but none of them were severe enough to require discontinuation of the treatment. The most common side effects in this study were upper respiratory tract infection (5 patients), bronchitis (3 patients), and influenza (1 patient).\[[@ref11]\] Cyclosporine is one of the most common drugs used in psoriasis treatment and many reports have been published on its side effects. Prajs and colleagues (2010) assessed the side effects of cyclosporine in 61 arthritis rheumatoid or psoriatic arthritis patients who also received MTX. The side effects included hypertension (19 patients), hand tremor (11 patients), hirsutism (7 patients), creatinine rise (17 patients), gingival hypertrophy (9 patients), abnormal appetite (2 patients), peripheral neuropathy, skin disorders, diarrhea and relapse of herpes zoster infection.\[[@ref12]\] Curtis and colleagues (2010) showed that combination therapy with MTX plus Leflunomide led to an increase in liver enzymes alanine/aspartate aminotransferase in 14% to 35% of the patients with psoriatic arthritis and rheumatoid arthritis.\[[@ref13]\] These studies showed that despite the reasonable response, caution should be exercised about the side effects of combinations.

The majority of the recent studies on combination therapy in psoriasis have focused on biologic treatments with MTX or routine non-biologic treatments such as cyclosporine, acitretin, or phototherapy.\[[@ref11][@ref14][@ref15][@ref16]\] These studies have showed that combination therapy results in more rapid healing without increasing the odds of side effects or toxicity in comparison with mono-therapy.

Because of the high costs of biologic treatments in Iran and also the challenges regarding moderate to severe psoriatic patients unresponsive to routine systemic non-biologic mono-therapy, and with regard to uncertainty about combination therapy due to probable occurrence of more complicated side effects than mono-therapy, we decided to investigate treatment with MTX, as one of the routine and low-cost anti-psoriatic modalities, in combination with other systemic non-biologic therapies in these patients.

The results of our study demonstrated that treatment with MTX in combination with other non-biologic systemic therapies is safe in difficult to manage psoriasis and leads to acceptable results.

Recommendation {#sec1-5}
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Due to the increasing rate of MTX administration in combination with biologic drugs worldwide, it is also reasonable to conduct further studies in Iran, with this regard.

**What is new?**

Although systemic combination therapy in psoriasis could have more potential side effects logically, MTX in combination with other non-biologic systemic modalities has acceptable results in terms of therapeutic outcomes and side effects in challenging cases.
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